Dare Bioscience Reports FY25 Results, Anticipates Q2 2026 Product Revenue & Highlights Strong Non-Dilutive Funding
DARE sits 19% above its 52-week low of $1.27 on elevated volume (2.4× avg).
Summary
Dare Bioscience reported full-year 2025 financial results, showcasing substantial revenue growth and a positive shift in working capital, alongside significant non-dilutive funding and the imminent commercial launch of multiple women's health products.
Key Events · Earnings and Guidance · DARE
-
Financial Performance & Improved Liquidity
Reported full-year 2025 revenue of $1.03 million (up from $9,784 in 2024) and a net loss of $(13.4) million (wider than $(4.1) million in 2024). Critically, working capital improved to $3.4 million (from a $3.2 million deficit in 2024) and cash and equivalents stood at $24.7 million as of December 31, 2025.
-
Significant Non-Dilutive Funding Secured
Received approximately $19.4 million in non-dilutive capital during 2025, including $13.6 million from the Gates Foundation, $4.5 million from an ARPA-H award, and $1.3 million in NIH grant reimbursements, substantially reducing reliance on equity financing.
-
Imminent Product Commercialization & Revenue Generation
DARE to PLAY™ Sildenafil Cream is now available for pre-fulfillment prescriptions nationally with telehealth access, and product revenue is expected to begin in Q2 2026. The first DARE to RESTORE™ product, Flora Sync LF5™, is also expected to be commercially available with revenue commencing in Q2 2026.
-
Advancing Key Pipeline Programs
Ovaprene® Phase 3 clinical study enrollment is anticipated to complete in 2026, with topline data expected in 2027. DARE-HPV is preparing to advance into a Phase 2 clinical study later in 2026 with ARPA-H funding, and DARE to RECLAIM™ is targeted for prescription fulfillment in early 2027.
Analysis · DARE · Life Sciences
This comprehensive annual report signals a pivotal transition for Dare Bioscience, moving from a pure R&D focus to commercialization with multiple products expected to generate revenue in Q2 2026. The significant non-dilutive funding, coupled with a positive swing in working capital and a robust cash position, provides crucial runway for a small biotech. Investors should monitor the successful launch and revenue generation of DARE to PLAY and DARE to RESTORE, as well as continued pipeline advancements, as these are critical for the company's long-term viability and valuation.
At the time of this filing, DARE was trading at $1.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.6M. The 52-week trading range was $1.27 to $9.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.